Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society
- PMID: 8000420
Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society
Abstract
1. A 6-mo regimen consisting of isoniazid, rifampin, and pyrazinamide given for 2 mo followed by isoniazid and rifampin for 4 mo is the preferred treatment for patients with fully susceptible organisms who adhere to treatment. Ethambutol (or streptomycin in children too young to be monitored for visual acuity) should be included in the initial regimen until the results of drug susceptibility studies are available, unless there is little possibility of drug resistance (i.e., there is less than 4% primary resistance to isoniazid in the community, and the patient has had no previous treatment with antituberculosis medications, is not from a country with a high prevalence of drug resistance, and has no known exposure to a drug-resistant case). This four-drug, 6-mo regimen is effective even when the infecting organism is resistant to INH. This recommendation applies to both HIV-infected and uninfected persons. However, in the presence of HIV infection it is critically important to assess the clinical and bacteriologic response. If there is evidence of a slow or suboptimal response, therapy should be prolonged as judged on a case by case basis. 2. Alternatively, a 9-mo regimen of isoniazid and rifampin is acceptable for persons who cannot or should not take pyrazinamide. Ethambutol (or streptomycin in children too young to be monitored for visual acuity) should also be included until the results of drug susceptibility studies are available, unless there is little possibility of drug resistance (see Section 1 above). If INH resistance is demonstrated, rifampin and ethambutol should be continued for a minimum of 12 mo. 3. Consideration should be given to treating all patients with directly observed therapy (DOT). 4. Multiple-drug-resistant tuberculosis (i.e., resistance to at least isoniazid and rifampin) presents difficult treatment problems. Treatment must be individualized and based on susceptibility studies. In such cases, consultation with an expert in tuberculosis is recommended. 5. Children should be managed in essentially the same ways as adults using appropriately adjusted doses of the drugs. This document addresses specific important differences between the management of adults and children. 6. Extrapulmonary tuberculosis should be managed according to the principles and with the drug regimens outlined for pulmonary tuberculosis, except for children who have miliary tuberculosis, bone/joint tuberculosis, or tuberculous meningitis who should receive a minimum of 12 mo of therapy.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention.Am J Respir Crit Care Med. 1994 May;149(5):1359-74. doi: 10.1164/ajrccm.149.5.8173779. Am J Respir Crit Care Med. 1994. PMID: 8173779
-
[Antitubercular chemotherapy].Rev Mal Respir. 1997 Dec;14 Suppl 5:S88-104. Rev Mal Respir. 1997. PMID: 9496594 Review. French.
-
American Thoracic Society. Medical Section of the American Lung Association: Treatment of tuberculosis and tuberculosis infection in adults and children.Am Rev Respir Dis. 1986 Aug;134(2):355-63. doi: 10.1164/arrd.1986.134.2.355. Am Rev Respir Dis. 1986. PMID: 3527010
-
Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.Int J Tuberc Lung Dis. 2002 Dec;6(12):1102-9. Int J Tuberc Lung Dis. 2002. PMID: 12546119 Clinical Trial.
-
Present status of chemotherapy for tuberculosis.Rev Infect Dis. 1989 Mar-Apr;11 Suppl 2:S347-52. doi: 10.1093/clinids/11.supplement_2.s347. Rev Infect Dis. 1989. PMID: 2652251 Review.
Cited by
-
Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania.PLoS One. 2015 Oct 26;10(10):e0141002. doi: 10.1371/journal.pone.0141002. eCollection 2015. PLoS One. 2015. PMID: 26501782 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical